ES470912A1 - Procedimiento para preparar compuestos heterociclicos - Google Patents

Procedimiento para preparar compuestos heterociclicos

Info

Publication number
ES470912A1
ES470912A1 ES470912A ES470912A ES470912A1 ES 470912 A1 ES470912 A1 ES 470912A1 ES 470912 A ES470912 A ES 470912A ES 470912 A ES470912 A ES 470912A ES 470912 A1 ES470912 A1 ES 470912A1
Authority
ES
Spain
Prior art keywords
derivatives
preparation
methods
pharmaceutical compositions
compositions containing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES470912A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of ES470912A1 publication Critical patent/ES470912A1/es
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/78—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Nuevos compuestos que tienen actividad relacionada con el GABA. El GABA (ácido gamma-aminobutírico) es un neurotransmisor en el sistema nervioso central (SNC) en los mamíferos. El GABA se encuentra predominantemente en el cerebro es un transmisor inhibidor dominante, y tiene varias propiedades farmacológicas interesantes, y muestra especialmente una inhibición de la funciones motrices.
ES470912A 1977-06-20 1978-06-19 Procedimiento para preparar compuestos heterociclicos Expired ES470912A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB2574077 1977-06-20

Publications (1)

Publication Number Publication Date
ES470912A1 true ES470912A1 (es) 1979-02-01

Family

ID=10232513

Family Applications (2)

Application Number Title Priority Date Filing Date
ES470912A Expired ES470912A1 (es) 1977-06-20 1978-06-19 Procedimiento para preparar compuestos heterociclicos
ES470913A Expired ES470913A1 (es) 1977-06-20 1978-06-19 Procedimiento para preparar aminoacidos ciclicos

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES470913A Expired ES470913A1 (es) 1977-06-20 1978-06-19 Procedimiento para preparar aminoacidos ciclicos

Country Status (14)

Country Link
US (2) US4278676A (es)
EP (4) EP0028017A1 (es)
JP (2) JPS5436275A (es)
AT (1) AT368505B (es)
AU (2) AU3724478A (es)
CA (1) CA1107736A (es)
DK (2) DK270278A (es)
ES (2) ES470912A1 (es)
FI (2) FI781955A7 (es)
IE (1) IE47200B1 (es)
IT (2) IT7868449A0 (es)
NO (3) NO782128L (es)
NZ (1) NZ187615A (es)
ZA (2) ZA783492B (es)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3145474A1 (de) * 1980-11-27 1982-09-02 Kefalas A/S, Koebenhavn-Valby 3-substituierte 4,5,6,7-tetrahydroisoxazolo(5,4-c)pyridinverbindungen, verfahren zu ihrer herstellung und diese enthaltende arzneimittel
DE3145473A1 (de) * 1980-11-27 1982-08-26 Kefalas A/S, Koebenhavn-Valby 2-substituierte 4,5,6,7-tetrahydroisoxazolo (5,4-c) pyridin-3-on-verbindungen, verfahren zu ihrer herstellung und diese enthaltende arzneimittel
EP0083378A1 (en) * 1981-12-22 1983-07-13 Chugai Seiyaku Kabushiki Kaisha Tetrahydronicotinamide derivatives, a process for producing the same and a pharmaceutical composition comprising the same
GB8314391D0 (en) * 1983-05-24 1983-06-29 Kefalas As Heterocyclic compounds
IT1228426B (it) * 1987-07-20 1991-06-17 Ausimont Spa Perossiacidi eterociclici
US4859666A (en) * 1988-07-06 1989-08-22 Bristol-Myers Company THAZ derivatives for enhancement of cerebral function
CN1043051C (zh) * 1994-07-22 1999-04-21 国际壳牌研究有限公司 制备氢化石蜡的方法
EP1641456B1 (en) 2003-06-25 2010-03-03 H. Lundbeck A/S Gaboxadol for treating depression and other affective disorders
US20050234093A1 (en) * 2003-06-25 2005-10-20 H. Lundbeck A/S Treatment of depression and other affective disorders
AR045540A1 (es) * 2003-09-05 2005-11-02 Lundbeck & Co As H Metodo de elaboracion de 4,5,6,7 tetrahidroisoxazol [5,4-c] piridin-3-ol (thip)
WO2005060968A1 (en) 2003-12-11 2005-07-07 Sepracor Inc. Combination of a sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression
US20050137222A1 (en) * 2003-12-18 2005-06-23 H. Lundbeck A/S Treatment of insomnia in human patients
US20050215521A1 (en) * 2003-12-22 2005-09-29 Karim Lalji Modafinil combination therapy for improving sleep quality
EP1696959A2 (en) * 2003-12-24 2006-09-06 Sepracor, Inc. Melatonin combination therapy for improving sleep quality
GB0402118D0 (en) * 2004-01-30 2004-03-03 Merck Sharp & Dohme Polymorphic forms of a GABAA agonist
CA2556870C (en) * 2004-02-18 2014-01-28 Timothy J. Barberich Dopamine-agonist combination therapy for improving sleep quality
GB0417558D0 (en) * 2004-08-06 2004-09-08 Merck Sharp & Dohme Novel combination therapy
EP1848420A4 (en) * 2005-01-28 2008-01-23 Merck & Co Inc POLYMORPH SHAPES OF A GABAA AGONIST
EP1906953A4 (en) * 2005-04-29 2009-05-20 Lundbeck & Co As H ACID AND BASE SALT FORMS OF GABOXADOL
JP2009506069A (ja) 2005-08-26 2009-02-12 ブレインセルス，インコーポレイティド ムスカリン性受容体調節による神経発生
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
US7985756B2 (en) 2005-10-21 2011-07-26 Braincells Inc. Modulation of neurogenesis by PDE inhibition
WO2007053596A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20070203216A1 (en) * 2006-02-14 2007-08-30 Bjarke Ebert Method of treating inflammatory diseases
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
WO2007134136A2 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
WO2007134077A2 (en) 2006-05-09 2007-11-22 Braincells, Inc. 5 ht receptor mediated neurogenesis
EP2068872A1 (en) 2006-09-08 2009-06-17 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
US20100193652A1 (en) * 2009-02-02 2010-08-05 William Stajos Wall Display System And Method Of Providing The Same
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
US8784835B2 (en) * 2012-07-02 2014-07-22 Trent Austin Method for producing muscimol and/or reducing ibotenic acid from amanita tissue
CN104974175A (zh) * 2014-04-11 2015-10-14 天津药物研究院 一种氨甲基羟异恶唑类似物的制备方法
ES2876350T3 (es) 2014-06-06 2021-11-12 Ovid Therapeutics Inc Métodos para aumentar la inhibición tónica y tratamiento del insomnio secundario
DK3274331T3 (da) * 2015-03-24 2020-03-23 H Lundbeck As Fremstilling af 4,5,6,7-tetrahydroisozaxolo[5,4-c]pyridin-3-ol
US9682069B2 (en) 2015-07-17 2017-06-20 Ovid Therapeutics Inc Methods of treating Dravet syndrome
KR20240160666A (ko) 2015-07-17 2024-11-11 오비드 테라퓨틱스 인크. 가복사돌로 발달장애들을 치료하는 방법들
US9399034B1 (en) 2015-08-11 2016-07-26 Ovid Therapeutics Inc Methods of sedation during critical care treatment
EP4233861A3 (en) 2016-08-11 2023-10-11 Ovid Therapeutics, Inc. Compositions for treatment of essential tremor
US10071083B2 (en) 2017-02-03 2018-09-11 Ovid Therapeutics Inc Use of gaboxadol in the treatment of tinnitus
US20180338959A1 (en) 2017-05-24 2018-11-29 Ovid Therapeutics Inc. Treatment of depressive disorders
US10813918B2 (en) 2017-08-04 2020-10-27 Ovid Therapeutics Inc. Use of Gaboxadol in the treatment of diabetes and related conditions
AU2019345312A1 (en) 2018-09-20 2021-03-25 Ovid Therapeutics Inc. Use of gaboxadol for the treatment of tourette syndrome, tics and stuttering
WO2020106927A1 (en) 2018-11-21 2020-05-28 Certego Therapeutics Gaboxadol for reducing risk of suicide and rapid relief of depression
CN113423399A (zh) 2018-12-17 2021-09-21 奥维德医疗公司 加波沙朵用于治疗非24小时睡眠-觉醒障碍的用途
MX2022014599A (es) 2020-05-20 2022-12-16 Certego Therapeutics Inc Gaboxadol deuterado en anillo y su uso para el tratamiento de trastornos psiquiatricos.
CN114292224B (zh) * 2022-03-07 2022-05-20 中国农业科学院农产品加工研究所 一种大麻二酚-2-（n-乙酰基）哌啶酸酯及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2784190A (en) * 1952-03-28 1957-03-05 Upjohn Co Alkyl piperidinepropionates
CA762455A (en) * 1962-03-22 1967-07-04 Dr. Karl Thomae Gesellschaft Mit Beschrankter Haftung Pyrido-pyrimidines
US3381016A (en) * 1966-03-04 1968-04-30 Upjohn Co Isoxazolo[5, 4-b]pyridine derivatives and a method for their preparation
DE2221770A1 (de) * 1972-05-04 1973-11-15 Bayer Ag Verfahren zur herstellung von tetrahydropyridinen
DK62791A (da) * 1991-04-09 1992-11-09 Tulip Int As Fremgangsmaade til saltning af koed samt anlaeg til brug ved udoevelse af fremgangsmaaden

Also Published As

Publication number Publication date
NO782128L (no) 1978-12-21
ES470913A1 (es) 1979-02-01
ZA783492B (en) 1979-06-27
NO782127L (no) 1978-12-21
DK270278A (da) 1978-12-21
NZ187615A (en) 1981-12-15
EP0000338B1 (en) 1981-11-25
EP0000338A3 (en) 1979-06-27
DK270378A (da) 1978-12-21
FI781954A7 (fi) 1978-12-21
AT368505B (de) 1982-10-25
ZA783493B (en) 1979-06-27
ATA448678A (de) 1982-02-15
US4278676A (en) 1981-07-14
JPS5436275A (en) 1979-03-16
CA1107736A (en) 1981-08-25
NO152049B (no) 1985-04-15
EP0000167A1 (en) 1979-01-10
EP0027279A1 (en) 1981-04-22
EP0000338A2 (en) 1979-01-24
FI64376C (fi) 1983-11-10
NO152049C (no) 1985-07-24
IE47200B1 (en) 1984-01-11
AU521040B2 (en) 1982-03-11
EP0028017A1 (en) 1981-05-06
IT7868449A0 (it) 1978-06-20
IT7868450A0 (it) 1978-06-20
US4301287A (en) 1981-11-17
AU3724478A (en) 1980-01-03
FI64376B (fi) 1983-07-29
JPS5436290A (en) 1979-03-16
IE781234L (en) 1978-12-20
FI781955A7 (fi) 1978-12-21
IT1159739B (it) 1987-03-04
NO792839L (no) 1978-12-21
AU3729878A (en) 1980-01-03

Similar Documents

Publication Publication Date Title
ES470913A1 (es) Procedimiento para preparar aminoacidos ciclicos
IL56346A (en) N-substituted omega-aminoalkanoyl-omega-aminoalkanoic acids,process for their production as well as pharmaceutical compositions containing these compounds
FR2399431A1 (fr) Derives du thiophene et procede pour leur preparation
FR2364913A1 (fr) Nouveaux derives du benzopyranne utiles comme medicaments et leur procede de preparation
IE780151L (en) Benzisoquinolines
ES462843A1 (es) Un procedimiento para la preparacion de compuestos imidazo (1,5-a) (1,4)diacepinicos.
FR2359133A1 (fr) Procede de preparation de (vinyl 2,2-disubstitue)-g-butyrolactones
FR2361876A1 (fr) 2,9-dioxatricyclo(4,3,1,03,7)decanes, procede pour leur preparation ainsi que les produits intermediaires convenant a cet effet
ES452277A1 (es) Procedimiento para la preparacion de 1, 1-diciclohexil-2- (2'-piperidil)-etano.
GR851642B (es)
IE43849L (en) Omega-thienyloxy-prostaglandins.
JPS51144722A (en) Process for preparing granules of lactose
JPS5440054A (en) Information process system
JPS51141855A (en) Process for preparing exo-hydroxy-endo-tricyclo-(5,2,2,02,6)undecane
JPS51138664A (en) Process for preparing 4-exo-hydroxy-endo-tri cyclo 95.2.2.02,6)-undeca-8-ene
JPS5231093A (en) Preparation of 3- methylenecephalosporanic acid derivatives
FR2421886A1 (fr) Procede de preparation de 1,2-diphenyl-3,5-dioxopyrazolidines substituees en position 4
OA06620A (fr) Procédé de préparation de nouveaux dérivés de décahydroquinoléinol.
OA05515A (fr) Procédé de préparation de nouveaux dérivés de décahydroquinoléine.
FR2372842A1 (fr) Procede pour la preparation d'esters de la 2,2'-anhydro-1b-d-arabinofuranosyl-5-fluorocytosine
OA05521A (fr) Procédé de préparation de nouveaux dérivés d'acétamidoxine.
IL49689A0 (en) Process for the preparation of 1,1-dihalo-1,3-dienes
JPS5214741A (en) Process for preparation of di-phenylalanine
BE846047A (fr) Procede de preparation d'esters de 1-phenyl 2,2,2-trihalogenoethanols substitues
AU502400B2 (en) Continuous process for purifying crude phosphoric acid